维普期刊资源整合服务平台（V6.5）

36篇 您的检索式：作者名="Higashi DL"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Associati- on between CYP2C9 genetic variants and anticoagula- tion-ra\|ated outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，87，13：	1
2	Association between CYP2C9 genetic variants and anticoagulation- related outcomes during warfarin therapy 显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
3	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy 显示文摘	Higashi MK Veenstra DL Kondo LM Wittkowsky AK Srinouanprachanh SL Farin FM	2002	JAMA2002，287，13：	1
4	Association between CYP2C9 genetic variants and antcoagula tionrelated outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA MA2002，287，13：	1
5	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy 显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
6	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy 显示文摘	HIGASHI MK VEENSTRA DL KONDO LM	2002	JAMA2002，287，13：	1
7	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy 显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
8	Presenilin/gammasecretase cleaves CD46 in response to Neisseria infection 显示文摘	Weyand NJ Calton CM Higashi DL	2010	J Immunol2010，184，2：	1
9	Association between CYP2C9 genetic variations anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM Wittkowsky AK Srinouanprachanh SL Farin FM	2002	JAMA2002，287，：	1
10	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
11	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy 显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
12	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi M Veenstra DL Wittkowsky AK	2002	JAMA2002，287，：	1
13	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM Wittkowsky AK Srinouanprachanh SL Farin FM	2002	JAMA2002，287，13：	1
14	Association between CYP2C9 genetic variations anticoagulation-related outcomes during warfarin therapy显示文摘	Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
15	Assessing the cost- effectiveness of pharmacogenomics 显示文摘	Veenstra DL Higashi MK Phillips KA	2000	APPS Pharm Sci2000，2，3：	1
16	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
17	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi M Veenstra DL Wittkowsky AK	2002	JAMA2002，287，：	1
18	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1
19	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM Wittkowsky AK Srinouanprachanh SL Farin FM	2002	JAMA2002，287，13：	1
20	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy显示文摘	Higashi MK Veenstra DL Kondo LM	2002	JAMA2002，287，13：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示